I undersøgelsen var incidensen af seponering på grund af hypertensionsrelaterede bivirkninger statistisk signifikant højere for etoricoxib end for diclofenac.
In the study, the incidence of discontinuations due to hypertension-related adverse events was statistically significantly higher for etoricoxib than for diclofenac.